<DOC>
	<DOCNO>NCT02238483</DOCNO>
	<brief_summary>The purpose study determine whether AZD7624 reduce acute Chronic Obstructive Pulmonary Disease ( COPD ) exacerbations patient COPD maintenance therapy history frequent acute exacerbation</brief_summary>
	<brief_title>A Phase IIa Study Investigate Efficacy Safety AZD7624 Chronic Obstructive Pulmonary Disease ( COPD ) Patients While Maintenance Therapy</brief_title>
	<detailed_description />
	<mesh_term>Lung Diseases</mesh_term>
	<mesh_term>Lung Diseases , Obstructive</mesh_term>
	<mesh_term>Pulmonary Disease , Chronic Obstructive</mesh_term>
	<criteria>Provision sign date write informed consent prior study specific procedure . Male female age 4085 year . Females must negative pregnancy test Visit 1 , must lactate must nonchildbearing potential . Males must surgically sterile agree use acceptable method contraception duration study 3 month last dose investigational product prevent pregnancy partner . A weight ≥50 kg . Diagnosis COPD 1 year Visit 1 , accord Global Initiative Chronic Obstructive Lung Disease ( GOLD ) 2014 guideline . COPD maintenance treatment least ICS/LABA least 2 month prior enrolment continue unchanged study . A postbronchodilator FEV1/FVC &lt; 0.70 postbronchodilator FEV1 ≤70 % predict normal value . Documented history 2 moderate severe COPD exacerbation within 12 month randomisation , within last 6 week randomisation . Current exsmokers smoke history least 10 packyears . Involvement plan conduct study . Previous randomisation present study . Participation another clinical study investigational medicinal product within 3 month randomisation . Previously intake p38 inhibitor . Participation , schedule intensive COPD rehabilitation programme time study . Planned inpatient surgery hospitalisation study . Significant disease disorder COPD , may either put patient risk participation study , influence result study , patient 's ability participate study . Asthma primary main diagnosis accord Global Initiative Asthma ( GINA ) guideline ( GINA 2013 ) accept guideline . A clinically relevant abnormal finding clinical chemistry , haematology urinalysis . Plasma myoglobin CK upper reference range analyse laboratory randomization . A clinically relevant abnormal finding physical examination , pulse blood pressure . A positive result screen serum hepatitis B hepatitis C Human Immunodeficiency Virus ( HIV ) . History family history muscle disease . Abnormal vital sign , define Systolic Blood Pressure ( SBP ) 140 mmHg &lt; 60 year age 150 mmHg ≥60 year age ; Diastolic Blood Pressure ( DBP ) 90 mmHg ; Pulse &lt; 50 &gt; 100 bpm . Prolonged QTcF &gt; 450 m family history long QT syndrome sudden death young age . PR ( PQ ) interval clinical significance , PR ( PQ ) &gt; 250 m . Intermittent AV block 2nd 3rd degree AV dissociation . Patients QRS duration &gt; 120 m . Patients persistent , and/or recurrent symptomatic tachyarrhythmias , well patient implantable cardioverterdefibrillator ( ICD ) permanent pacemaker . Patients recent Cardiovascular ( CV ) event unstable CV disease myocardial infarction stroke within 6 month screen . History hospitalization within 12 month cause heart failure diagnosis heart failure high New York Heart Association ( NYHA ) class II . History severe allergy/hypersensitivity ongoing clinically important allergy/hypersensitivity history hypersensitivity drug similar chemical structure class AZD7624 . Any exacerbation respiratory infection within 6 week randomization . Plasma donation within one month Visit 1 , blood donation/blood loss &gt; 500 mL 3 month prior Visit 1 . History , current alcohol drug abuse . Treatment GCS ( apart prescribe steroid runin ) within 6 week Visit 3 regardless indication . Treatment strong CYP3A inhibitor within 4 week prior randomisation .</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>April 2016</verification_date>
	<keyword>Chronic Obstructive Pulmonary Disease</keyword>
	<keyword>COPD patient</keyword>
	<keyword>Exacerbations</keyword>
	<keyword>ICS</keyword>
	<keyword>LABA</keyword>
</DOC>